Post by Ypsomed AG

How can platform-based development help accelerate clinical programs for drug-device combination products 🚀? This was one of the key themes discussed at this year's Combination Products Summit, organized by PharmaEd, where Karolína Šnajdarová shared Ypsomed's perspective on streamlining development through platform technologies, expert support, and strategic partnerships 🤝. A particular focus was the Molecule-Independent Device Bridging Approach (MIDBA), recently qualified by the EMA. Ypsomed played a vital role, with our YpsoMate 1 mL and YpsoMate 2.25 mL autoinjector platforms used to demonstrate the validity of this groundbreaking approach ✅. Read Karolína's full conference recap and key takeaways here 👉 https://brnw.ch/21x3tnE Pharma Ed Resources Events #regulatory #expertise #MIDBA #YpsoMate #ypsomed